Wordt geladen...
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternat...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685399/ https://ncbi.nlm.nih.gov/pubmed/23807861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S45193 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|